Details for Patent: 10,995,337
✉ Email this page to a colleague
Which drugs does patent 10,995,337 protect, and when does it expire?
Patent 10,995,337 protects VYONDYS 53 and is included in one NDA.
This patent has thirty patent family members in thirteen countries.
Summary for Patent: 10,995,337
Title: | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Abstract: | An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214. |
Inventor(s): | Wilton; Stephen Donald (Applecross, AU), Fletcher; Sue (Bayswater, AU), McClorey; Graham (Bayswater, AU) |
Assignee: | The University of Western Australia (Crawley, AU) |
Application Number: | 16/881,430 |
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 10,995,337
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970-001 | Dec 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,995,337
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E498685 | ⤷ Try a Trial | |||
Cyprus | 1111447 | ⤷ Try a Trial | |||
Cyprus | 1117475 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |